Estrogen receptor modulators
View Patent ↗The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
1. A compound of the formula:
wherein X is O— or N—OH;
R 1 is hydrogen, fluoro, chloro, bromo, iodo, or C 1-4 alkyl, wherein said alkyl group is optionally substituted with 1, 2 or 3 groups selected from the group consisting of fluoro, chloro, and bromo;
R 2 is hydrogen;
R 3 is hydrogen;
R 4 is hydrogen;
R 5 is hydrogen;
or a pharmaceutically acceptable salt; or a stereoisomer thereof.
2. The compound of claim 1 which is 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno [4,5-d][1,2,3]triazol-7(8H)-one;
6-chloro-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one;
6-bromo-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; 6-chloro-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one oxime; and
6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one oxime;
or a pharmaceutically acceptable salt; or a stereoisomer thereof.
3. The compound of claim 2 which is
(8R,10aS)-6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][,1,2,3]triazol-7(8H)-one;
(8R,10aS)-6-chloro-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one;
(8R,10aS)-6-bromo-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno [4,5-d][1,2,3 ]triazol-7(8H)-one;
(8R,10aS)-6-chloro-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1 ,2,3]triazol-7(8H)-one oxime; and
(8R,10aS)-6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one oxime;
or a pharmaceutically acceptable salt thereof.
4. A compound which is (8R,10aS)-6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one.
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a compound of claim 1 and another agent selected from the group consisting of an organic bisphosphonate; a cathepsin K inhibitor; an estrogen; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent; calcitonin; Vitamin D; a synthetic Vitamin D analogue; a selective serotonin reuptake inhibitor; an aromatase inhibitor; or a pharmaceutically acceptable salt or mixture thereof, and a pharmaceutically acceptable carrier.
7. A method for treating uterine fibroid disease, hot flashes, perimenopausal depression, or premenstrual syndrome in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1 .
8. A method for treating uterine fibroid disease, hot flashes, perimenopausal depression, or premenstrual syndrome in mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a composition of claim 6 .
9. A compound selected from 6-phenyl-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno [4,5-d][1,2,3]triazol-7(8H)-one, and 6-phenyl-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one oxime; or a pharmaceutically acceptable salt or a stereoisomer thereof.
10. The compound of claim 9 selected from (8R,10aS)-6-phenyl-3,9,10,11 -tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one, and (8R, 10aS)-6-phenyl-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno [4,5-d][1,2,3]triazol-7(8H)-one oxime; or a pharmaceutically acceptable salt thereof.
11. The compound of claim 3 , which is (8R,10aS)-6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; or a pharmaceutically acceptable salt thereof.
12. The compound of claim 2 , which is 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one or a pharmaceutically acceptable salt thereof; or a stereoisomer thereof.
13. The compound of claim 2 , which is 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one.
14. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.
16. A method for treating uterine fibroid disease, hot flashes, perimenopausal depression, or premenstrual syndrome in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of the compound of claim 4 .
17. A method for treating uterine fibroid disease, hot flashes, perimenopausal depression, or premenstrual syndrome in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of the compound of claim 13 .